Immunic, Inc. (IMUX)
NASDAQ: IMUX · Real-Time Price · USD
0.8889
+0.0596 (7.19%)
Aug 14, 2025, 1:53 PM - Market open
Immunic Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
91
Market Cap
87.69M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
IMUX News
- 7 days ago - Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update - PRNewsWire
- 7 weeks ago - Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis - PRNewsWire
- 2 months ago - Immunic Post-Readout: Reiterating Strong Buy As Big Drop Appears Unwarranted - Seeking Alpha
- 2 months ago - Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS - PRNewsWire
- 2 months ago - Immunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public Offering - PRNewsWire
- 2 months ago - Immunic to Participate in Investor, Scientific and Industry Conferences in June - PRNewsWire
- 2 months ago - Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering - PRNewsWire
- 2 months ago - Immunic, Inc. Announces Proposed Public Offering - PRNewsWire